Disease-Free Survival Data from CAPTIVATE Study Demonstrate Benefit of IMBRUVICA® (ibrutinib)-Based Regimen as Fixed Duration, First-Line Treatment for Patients with Chronic Lymphocytic Leukemia ...Middle East

RARITAN, N.J., Dec. 5, 2020 /PRNewswire/ -- New data from the Phase 2 CAPTIVATE study were presented today during an oral session at the 2020 American Society of Hematology (ASH) Annual Meeting (Abstract #123). The study evaluated the efficacy and safety of IMBRUVICA® (ibrutinib) plus...

Hence then, the article about disease free survival data from captivate study demonstrate benefit of imbruvica ibrutinib based regimen as fixed duration first line treatment for patients with chronic lymphocytic leukemia was published today ( Saturday 05/12/2020 - 09:01 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Disease-Free Survival Data from CAPTIVATE Study Demonstrate Benefit of IMBRUVICA® (ibrutinib)-Based Regimen as Fixed Duration, First-Line Treatment for Patients with Chronic Lymphocytic Leukemia )

Also on site :

• Your citizens don't stay put in Stellaris-style 4X strategy game Final Vanguard - start a war and "entire waves of refugees can emerge"
• Labour doesn’t care about protecting countryside, voters say
• Shropshire cricket ace lands Warwickshire captaincy role